XRRA1 Antibody, Biotin conjugated
-
中文名稱：XRRA1兔多克隆抗體, Biotin偶聯(lián)
-
貨號(hào)：CSB-PA747397LD01HU
-
規(guī)格：￥880
-
其他：
產(chǎn)品詳情
-
產(chǎn)品名稱：Rabbit anti-Homo sapiens (Human) XRRA1 Polyclonal antibody
-
Uniprot No.：
-
基因名：XRRA1
-
別名：XRRA1 antibody; X-ray radiation resistance-associated protein 1 antibody
-
宿主：Rabbit
-
反應(yīng)種屬：Human
-
免疫原：Recombinant Human X-ray radiation resistance-associated protein 1 protein (101-400AA)
-
免疫原種屬：Homo sapiens (Human)
-
標(biāo)記方式：Biotin
-
克隆類型：Polyclonal
-
抗體亞型：IgG
-
純化方式：>95%, Protein G purified
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 -
產(chǎn)品提供形式：Liquid
-
應(yīng)用范圍：ELISA
-
Protocols：
-
儲(chǔ)存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情
-
功能：May be involved in the response of cells to X-ray radiation.
-
基因功能參考文獻(xiàn)：
- our results identify a novel link between XRRA1 and the ATM/CHK1/2 pathway and suggest that XRRA1 is involved in a DNA damage response that drives radio- and chemoresistance by regulating the ATM/CHK1/2 pathway. PMID: 29082250
- Molecular cloning and gene expression patterns of XRRA1. PMID: 12908878
-
亞細(xì)胞定位：Cytoplasm. Nucleus.
-
組織特異性：Expressed predominantly in testis followed by prostate and ovary. Low levels found in other tissues including peripheral blood leukocytes, spleen, thymus, small intestine and colon. Also expressed in neuroblastoma, glioma, breast, lung, leukemia, renal, o
-
數(shù)據(jù)庫(kù)鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
-
-
-
-
-
